Less intense treatment for early ER-positive breast cancer
Part of Cancer clinical trials.
This trial tests whether a less intense treatment plan (de-escalation) is safe and effective for women with early-stage, ER-positive, HER2-negative breast cancer. It aims to reduce side effects while keeping outcomes excellent.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- Your breast cancer is stage I (tumor 2 cm or smaller and no cancer in lymph nodes).
- Your cancer is ER-positive (at least 50% of cells have estrogen receptors) and HER2-negative.
- Your cancer has a low proliferation rate (Ki-67 20% or less).
- You have at least one of these low-risk features: tumor 1 cm or smaller, a low Oncotype DX score, a specific digital pathology subtype, or age 65 or older.
- You have not had any prior cancer treatment (chemotherapy, radiation, hormone therapy) for this breast cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatment approaches in people with high-risk hormone-positive, HER2-negative breast cancer that has spread to certain lymph nodes. It looks at which option works best to lower cancer returning and to control the disease after surgery and initial chemotherapy.
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
This trial tests a stronger treatment (a CDK4/6 inhibitor) combined with less chemotherapy for early-stage breast cancer that is positive for hormone receptors and HER2. It aims to see if this approach works well while reducing side effects from chemo.
This Phase 2 study tests whether treatment can be reduced (de-escalated) for people with early-stage (stage I) HER2-positive invasive breast cancer. It aims to keep the cancer under control while potentially reducing treatment intensity and side effects.
This trial studies early, hormone receptor–positive, HER2-negative breast cancer and looks at a group with “high clinical risk” but “low genetic (tumor) risk.” It may help researchers understand which patients may benefit most from treatment decisions guided by genetic tumor testing.
This trial tests whether a customized treatment plan given before surgery can improve outcomes for women with early-stage HR-positive, HER2-positive breast cancer. The goal is to shrink the tumor and make surgery more effective.
Hear when a new Breast Cancer Early Stage Breast Cancer (Stage 1-3) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.